{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:27:26Z","timestamp":1787113646258,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejca.2026.116886","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:42:09Z","timestamp":1781278929000},"page":"116886","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials"],"prefix":"10.1016","volume":"244","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3049-0904","authenticated-orcid":false,"given":"Kenta","family":"Iguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6269-9345","authenticated-orcid":false,"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8339-2895","authenticated-orcid":false,"given":"Toshihiro","family":"Misumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5041-2765","authenticated-orcid":false,"given":"Hideaki","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-9366","authenticated-orcid":false,"given":"Eiji","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4863-8682","authenticated-orcid":false,"given":"Jean-Yves","family":"Douillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Koopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6071-7810","authenticated-orcid":false,"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9749-6548","authenticated-orcid":false,"given":"Alan P.","family":"Venook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6480-304X","authenticated-orcid":false,"given":"Yoshihiko","family":"Maehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goro","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5103-7095","authenticated-orcid":false,"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimery","family":"de Gramont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0489-4756","authenticated-orcid":false,"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116886_bib1","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2026.116886_bib2","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","volume":"32","author":"Schwartzberg","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116886_bib3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41416-020-01140-9","article-title":"FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial","volume":"124","author":"Heinemann","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2026.116886_bib4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116886_bib5","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial","volume":"329","author":"Watanabe","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2026.116886_bib6","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1136\/gutjnl-2012-302014","article-title":"Colorectal cancer: a tale of two sides or a continuum?","volume":"61","author":"Yamauchi","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.ejca.2026.116886_bib7","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.3390\/cancers17213438","article-title":"Genetic, epidemiological, clinical, and therapeutic trajectories in colon and rectal cancers","volume":"17","author":"Capuozzo","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2026.116886_bib8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12943-025-02327-5","article-title":"Does side matter? Deciphering mechanisms that underpin side-dependent pathogenesis and therapy response in colorectal cancer","volume":"24","author":"Boka","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ejca.2026.116886_bib9","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1158\/1078-0432.CCR-17-2484","article-title":"Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes","volume":"24","author":"Loree","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116886_bib10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.6004\/jnccn.2020.7619","article-title":"Microsatellite instability and KRAS mutation in stage IV colorectal cancer: prevalence, geographic discrepancies, and outcomes from the National Cancer Database","volume":"19","author":"Uhlig","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2026.116886_bib11","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.62347\/JOGM1897","article-title":"A comparative genomic analysis of left- and right-sided colon cancer using real-world data from the AACR project GENIE BPC dataset","volume":"15","author":"Kim","year":"2025","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.ejca.2026.116886_bib12","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116886_bib13","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116886_bib14","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa0808268","article-title":"Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer","volume":"360","author":"Tol","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116886_bib15","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdq632","article-title":"Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study","volume":"22","author":"Bokemeyer","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116886_bib16","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116886_bib17","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s12885-017-3360-z","article-title":"TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group","volume":"17","author":"Cremolini","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2026.116886_bib18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41416-019-0518-2","article-title":"Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)","volume":"121","author":"Oki","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2026.116886_bib19","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1634\/theoncologist.2017-0640","article-title":"Randomized phase II trial of CapOX plus bevacizumab and CapIRI plus bevacizumab as first-line treatment for Japanese patients with metastatic colorectal cancer (CCOG-1201 study)","volume":"23","author":"Nakayama","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2026.116886_bib20","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/annonc\/mdx816","article-title":"S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial","volume":"29","author":"Yamada","year":"2018","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116886_bib21","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JGO.19.00367","article-title":"Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline","author":"Chiorean","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.ejca.2026.116886_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101558","article-title":"Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer","volume":"8","author":"Yoshino","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.116886_bib23","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of metastatic colorectal cancer: ASCO guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116886_bib24","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-023-02791-w","article-title":"Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116886_bib25","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3390\/cancers14030526","article-title":"Exact primary tumor location in mCRC: prognostic value and predictive impact on anti-EGFR mAb efficacy","volume":"14","author":"Alig","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2026.116886_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103677","article-title":"Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI","volume":"9","author":"Alig","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.116886_bib27","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(23)00219-X","article-title":"First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group","volume":"24","author":"Bond","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116886_bib28","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41416-021-01477-9","article-title":"Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone","volume":"125","author":"Ten Hoorn","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2026.116886_bib29","article-title":"Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literature","volume":"10","author":"Chan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2026.116886_bib30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2017.07.016","article-title":"Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes","volume":"84","author":"Stintzing","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116886_bib31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.6004\/jnccn.2017.0038","article-title":"Right versus left colon cancer biology: integrating the consensus molecular subtypes","volume":"15","author":"Lee","year":"2017","journal-title":"J Natl Compr Cancer Netw"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:14:51Z","timestamp":1787112891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"alternative-id":["S0959804926006672"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116886","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116886","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116886"}}